Sign in to view content

Time to Dry Analysis of Brolucizumab Versus Aflibercept in Patients With Neovascular AMD: 96-Week Data From HAWK and HARRIER Trials

Carl D. Regillo, MD

Video
Published 2019

Carl D. Regillo, MD, FACS

AMD Neovascular Part I

Related

Episode 10: Cytokines Levels and Response to Ranibizumab in DME with Dr. Rajeev Muni
Keyvan Koushan, MD, FRCSC
Member Podcasts
2018
What Happens to Diabetic Retinopathy Severity Scores With Less Aggressive Treatment? A Post Hoc Analysis of the RISE and RIDE Open Label Extension Study
Roger A. Goldberg, MD, MBA
Annual Meeting Talks
2019
Episode 17: 5-year Results of DRCR.net Protocol S: PRP laser vs Ranibizumab for PDR with Dr. Jennifer Sun
Keyvan Koushan, MD, FRCSC
Member Podcasts
2018

Category: AMD-Neovascular

See more